Lenalidomide and pomalidomide based triplet combination regimens for myeloma patients receives approval from the European Commission

Access, MyelomaLeave a comment

The European Commission has approved two of Celgene’s IMiD ® -based combination regimens: Lenalidomide (Revlimid®) in combination with bortezomib and dexamethasone (RVd) in adult patients with previously untreated multiple myeloma who are not eligible for transplant Pomalidomide (Imnovid®) in combination with bortezomib and dexamethasone (PVd), in adult patients with multiple myeloma, who have received at least one prior treatment regimen including lenalidomide.

Advocacy sessions at EHA Annual Meeting 2019

AL amyloidosis, Conferences, MyelomaLeave a comment

  The European Hematology Association (EHA) celebrates its Annual Meeting in Amsterdam, from 13 to 16 June. This is the most important congress of haematology in Europe in which latest developments and cutting-edge research in haematological diseases will be discussed. Find more information about the congress here. For the first time, the session covering advocacy topics (both Patient Advocacy Track and EHA Advocacy Sessions) have been merged into the Joint EHA-Patient Symposium on Policy Challenges…

Call to action for Central and Eastern European (CEE) members – join MPE CEE workgroup on access

Access, MPELeave a comment

Myeloma Patients Europe (MPE) has launched a Central and Eastern Europe (CEE) Workgroup on Access during our recent Annual General Meeting (AGM) in Munich, Germany. The Workgroup is chaired by MPE board members, Kristina Modic, also CEO of our Slovenian member Slovensko Združenje Bolnikov Z Limfomom In Levkemijo L&L, and Biba Dodeva, President of our Macedonian member BORKA. It was launched in response to an identified need for coordinated action at a European level on…

Results of MPE members participation in EMA survey on bortezomib

MPE, Myeloma, Patient evidenceLeave a comment

As bortezomib, an anti-myeloma medicine, is licensed as both an intravenous (IV – through the vein via a drip) and subcutaneous medicine (through the skin, via an injection), the European Medicines Agency (EMA) recently conducted a survey to understand which method was most commonly used across Europe. They also asked about the location of administration (i.e. at home or in hospital) for patients.

Myeloma Patients Europe webinar on CAR-T cell treatment

MPE, MyelomaLeave a comment

Patient advocates, patients and caregivers have heard a lot about CAR-T cell treatment and its potential in myeloma. However, there are still a lot of questions about its benefits, its challenges and its role in treating myeloma. With the aim of providing an overview of CAR-T cell treatment in myeloma, healthcare professional expectations and an introduction to some of the advantages and challenges for patients and in bringing it to market, Myeloma Patients Europe (MPE) will…

ESMO drives EU-level action to tackle shortages of essential medicines

AccessLeave a comment

Shortages of essential cancer medicines have a direct impact on patient care across Europe. To ensure that this issue remains a top priority on the EU policy agenda, the European Society for Medical Oncology (ESMO) collaborated with the European Parliament to organise a cross-partisan event entitled “Shortages of Inexpensive, Essential Medicines: Calling for Tangible Political Commitments in the EU”, according to a press release sent by ESMO today.

CARAMBA at the 1st European CAR-T Cell Meeting in Paris

MPE, MyelomaLeave a comment

The European Hematology Association (EHA) and European Society for Blood and Marrow Transplantation (EBMT) held the first European CAR T Cell Meeting together in Paris on February 14-16, 2019. Chimeric Antigen Receptor T-cell therapy (CAR-T) is revolutionizing the field of hematologic malignancies and has the potential to achieve cure for a number of dreadful diseases. The recent approvals of the first CAR T Cell treatments in Europe provide a great opportunity to fight hematologic malignancies,…